Business context and reporting period
Filing mismatch: The supplied filing is IKONICS Corporation’s 2019 Form 10-K (ticker IKNX), not a TeraWulf Inc. filing. It covers the fiscal year ended December 31, 2019, with 2018 comparisons; it does not provide standalone fourth-quarter results.
IKONICS develops and manufactures imaging products and operates four reportable segments: Chromaline, IKONICS Imaging, Digital Texturing (DTX), and Advanced Material Solutions (AMS). Its products serve screen printing, awards and recognition, aerospace, electronics, automotive, and related markets. Foreign sales were 29.4% of sales in both years.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Net sales | $17.62 million | $18.21 million |
| Gross profit / margin | $5.40 million / 30.6% | $6.25 million / 34.3% |
| Operating income (loss) | $(957,000) | $226,000 |
| Net income (loss) | $(814,000) | $139,000 |
| Basic and diluted EPS | $(0.41) | $0.07 |
| Cash from (used in) operating activities | $(477,000) | $1.225 million |
SG&A was $5.48 million, up from $5.35 million; R&D increased to $870,000 (4.9% of sales) from $677,000 (3.7%). The 2019 tax benefit was $172,000, versus $46,000 tax expense in 2018.
At year-end, cash and cash equivalents were $964,000 and short-term investments were $2.205 million, together down from $4.318 million in 2018. Current assets were $8.692 million and current liabilities $1.934 million. The company reported $2.822 million of balance-sheet debt, with $2.917 million principal outstanding before unamortized issuance costs. A $2.05 million asset-secured credit line was undrawn.
Investing activities provided $8,000 in 2019, including purchases and maturities of short-term investments; capital expenditures were $478,000. Financing activities used $190,000, including $140,000 of debt principal payments and $50,000 of share repurchases.
Material changes versus 2018
- Sales fell 3.3%, while gross margin declined 3.7 percentage points; the company moved from operating and net income to losses.
- Chromaline sales declined 1.2%; lower domestic sales and a shift toward lower-margin Asia sales, Chinese tariffs, and higher raw-material prices weighed on its margin, which fell to 26.9% from 31.5%.
- IKONICS Imaging sales declined 4.7%, and its margin fell to 45.8% (the filing’s MD&A appears to contain a year typo when describing this comparison; the comparison is with 2018’s 47.2%). AMS sales fell 12.5%, and its margin declined to 10.3% from 13.2%. DTX sales declined 6.4%; margin was 60.0%, down from 67.4%.
- Operating cash flow swung from $1.225 million provided to $477,000 used, reflecting the net loss and working-capital movements, including increases in receivables, inventory, and prepaid expenses.
By segment, 2019 operating income was $1.25 million for Chromaline, $836,000 for IKONICS Imaging, and $86,000 for DTX; AMS recorded a $201,000 operating loss. Unallocated costs were $2.93 million.
Outlook, risks, and unusual items
- Management expected approximately $350,000 of 2020 capital expenditures, mainly production-equipment upgrades and vehicle replacements, funded from operating cash. No quantified revenue or earnings guidance was provided.
- Management planned to continue R&D investment, product development, and commercialization efforts. It cited three long-term AMS sales agreements with major aerospace companies, ongoing DTX initiatives, and positive early reception for the IKONART product.
- The company breached its debt-service-coverage covenant at December 31, 2019, but obtained a waiver. In February 2020, it amended the calculation to an annual test beginning December 31, 2020. The loan has a potential bond tender date of April 1, 2021 that could require repayment of outstanding principal and interest. Management said liquidity resources mitigated the risk, but future waivers are not assured.
- The CEO transition was announced in January 2020: Glenn Sandgren became CEO effective February 10, and William Ulland remained chairman. The company expected approximately $375,000 of one-time first-quarter 2020 transition costs.
- Other notable items include a $93,000 write-off of abandoned patent-application costs and a $214,000 deferred-tax valuation allowance. The filing cites cumulative losses over the three years ended 2019 as negative evidence concerning realization of deferred tax assets.
- Principal risks include market acceptance and profitability of AMS and DTX, economic and aerospace/automotive industry volatility, competition, tariffs and raw-material costs or supply, reliance on a single DTX printer manufacturer, distributor and international-market risks, environmental compliance, intellectual-property protection, and cybersecurity. The filing specifically discusses potential disruption from pandemics, including coronavirus.
RSM US LLP issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer identity: this source is IKONICS Corporation (IKNX), not TeraWulf Inc.
- Review the debt covenant waiver, February 2020 amendment, and potential April 2021 bond tender or repayment provisions.
- Assess the drivers of weaker sales, lower segment margins, and the operating-cash-flow reversal, including working-capital changes.
- Track whether AMS and DTX initiatives generate sustained sales and profits, and whether the three AMS agreements translate into orders.
- Verify the 2020 CEO-transition costs, planned capital expenditures, and deferred-tax-asset valuation assumptions against subsequent filings.